Revista Portuguesa de Investigação Comportamental e Social 2019 Vol. 6 (1): 40-49
Portuguese Journal of
Behavioral and Social Research 2019 Vol. 6 (1): 40-49
Departamento de Investigação & Desenvolvimento • Instituto
Superior Miguel Torga
ARTIGO ORIGINAL
Depressive
symptoms in Type 1 and Type 2 Diabetes Mellitus
and its relationship with glycemic control
Sintomas depressivos em pacientes com Diabetes Mellitus Tipo 1 e Tipo 2 e sua
relação com o controlo glicémico
Ilda Massano-Cardoso (1,2,3)
Fernanda Daniel (1,3)
Vítor Rodrigues (2)
Ana Galhardo (1,4)
(1) Inst Sup
Miguel Torga, Coimbra, Portugal
(2) Univ Coimbra, FMUC,
Portugal
(3) Univ Coimbra,
CEISUC, FEUC, Portugal
(4) Univ Coimbra, CINEICC,
FPCEUC, Portugal
Recebido: 07/02/2020; Revisto: 13/03/2020; Aceite: 24/04/2020.
https://doi.org/10.31211/rpics.2020.6.1.166
Abstract
Objective:
The current study assessed depressive symptoms in Type 1 Diabetes
Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM) patients and explored
whether these symptoms were associated with glycemic control. Methods: A cross-sectional design was
used. Patients attending diabetes consultations participated in the study (N
= 347). Participants completed the Beck Depression Inventory (BDI), and
glycemic control was based on A1C criteria. Results: The mean score on the BDI, for either T1DM or T2DM, was
not clinically significant and was not associated with diagnosis duration. The
association between depression and glycemic control was significant in both DM
types. T2DM participants presenting more depressive symptoms were those with
greater glycemic control. T1DM and T2DM differences regarding depressive
symptoms were in somatic symptoms. Conclusions:
In T2DM depressive symptoms may be confounded with DM physical consequences.
There is also the possibility that negative mood plays a mediating role in
mobilizing survival strategies that promote glycemic control. Furthermore, the
assessment of depressive symptomatology in patients with diabetes could benefit
from the availability of a disease-specific measure.
Palavras-Chave: Diabetes mellitus; Type 1 diabetes; Type 2 diabetes;
Depressive symptoms; Glycemic control.
Resumo
Objetivo: O presente estudo procurou avaliar a presença
de sintomas depressivos em pacientes com diabetes mellitus tipo 1 (T1DM) e tipo 2
(T2DM), explorando a sua associação com o controlo glicémico. Métodos: Estudo de desenho transversal.
Participaram no estudo 347 pacientes com um diagnóstico de diabetes mellitus tipo 1 e
tipo 2, os quais preencheram um questionário sociodemográfico e clínico e o
Inventário Depressivo de Beck (BDI). Os valores do
controlo glicémico foram facultados pelo clínico assistente, sendo baseados no
critério de hemoglobina glicada (A1C). Resultados:
O score médio do BDI total para os pacientes com T1DM ou T2DM não se revelou
clinicamente significativo e não se encontrou associado à duração da doença. A
associação entre sintomas depressivos e controlo glicémico foi significativa em
ambos os tipos de diabetes. Os pacientes com T2DM que apresentaram mais
sintomas depressivos foram os que evidenciavam maior controlo glicémico. As
diferenças observadas nos sintomas depressivos dos pacientes com T1DM e T2DM
manifestaram-se nos sintomas somáticos avaliados pelo BDI. Conclusões: Os sintomas depressivos nos pacientes com T2DM podem
ser confundidos com as consequências físicas da própria diabetes. De referir
igualmente a possibilidade de o humor negativo desempenhar um papel mediador na
mobilização das estratégias promotoras de um adequado controlo glicémico.
Keywords: Diabetes mellitus; Diabetes tipo 1; Diabetes tipo 2; Sintomas
depressivos; Controlo glicémico.
Introduction
Diabetes mellitus (DM) integrates a heterogeneous group of metabolic
disorders characterized by the body's inability to maintain glucose
homeostasis. In 2019, this public health problem affected 463 million adults,
and this will rise to 700 million in 2045 (International Diabetes Federation, 2020). Furthermore, 30%
to 80% of cases remain undiagnosed, this being a major challenge in public
health (World Health
Organization [WHO], 2011). Type 2 DM (T2DM) is the most common,
being responsible for 95% or more of the total cases. It is closely associated
with lifestyle factors (e.g., diet and physical activity levels). T2DM is has a
higher prevalence among middle-aged and older individuals, although it is
increasingly appearing in overweight children, adolescents, and young adults (WHO, 2016). T1DM is less
prevalent (3-5% of all cases of DM) and affects children and young adults,
particularly. T1DM is characterized by the pancreatic beta-cell mass
destruction, being these cells responsible for producing insulin. Although not
fully understood, the origin of T1DM seems to be related to an overaggressive
autoimmune response, which leads to the failure of pancreatic endocrine
function (Kahanovitz et al., 2017).
There is consensus in the fact that that
depression is commonly associated with chronic illnesses (e.g., Gonzalez et al., 2007; Park et al., 2004). Depression tends
to appear as a comorbid condition in patients suffering from chronic diseases,
as in the case of DM (Chireh & D'Arcy,
2019). It is common to observe an increase in symptomatology and
medical costs, a decline in adherence to prescribed therapies, as well as a
greater risk of morbidity and mortality (Son et al., 2011), specifically in terms of DM, a proportion of DM patients (20-40%)
experience emotional difficulties, ranging from disorders specifically related
to the disease to general symptoms of anxiety and depression (Son et al., 2011). Regarding depression, it constitutes not only a risk factor for the
development of DM but is also a psychiatric condition highly prevalent in DM
patients (WHO, 2003). Prospective
studies with representative samples (1715, 2662, and 2764 individuals) showed
that depression appears as a risk factor for the diagnosis of DM with a
prevalence of 20% to 30% (Fráguas et al., 2009). In a
systematic review of the epidemiological aspects of depression, the prevalence
of this mood disorder in DM patients ranged from 0% to 60.5% (Moreira et al., 2003). Independently of these mixed results, it is
estimated that depression is two to four times higher in the DM population than
in the healthy population (Silva, 2006). Moreover, the
association between depressive symptoms and poor glycemic control (Guedes et
al., 2016) and depression and diabetes
complications (Nouwen et
al., 2019) has been previously reported.
Adherence to long-term therapies for
patients in developed countries is expected to achieve 50%, whereas, for
developing countries, it tends to exhibit a smaller percentage, given the lack
of resources and inequality of access to health care (WHO, 2003). Some studies point
to non-adherence rates ranging from 4% to 92%, stating that these rates usually
vary between 30% and 60% (Masek &
Janke, 1982). The WHO study "The
COst of Diabetes in Europe – Type 2 [CODE-2]"
states that 28% of patients pursuing treatment for DM achieve glucose control (WHO, 2003). In the United
States, less than 2% of DM adults carry out the ADA's highest recommended level
of health care. These percentages are related to the fact that keeping DM under
control requires more than simply taking medication (Costa et
al., 2011; Fráguas et
al., 2009; Guedes et al., 2016; Moreira et al., 2003; Silva, 2010; WHO, 2003). The literature
reports that multiple factors influence a person's level of adherence to
treatment. In addition to the precision associated with the administration of
pharmacological therapies, patients are requested to engage in health promotion
behaviors and, for most of them, to change their lifestyles. The centrality of
the patient's role in self-administered health care management is a crucial
topic. Adherence to treatment does not imply simply the scrupulous following of
the medical regimen; it also entails engaging in several health-related
behaviors, such as eating behaviors or physical activity (WHO, 2003). Indeed, DM implies
the measurement of a wide range of intervening factors related to glycemic
control. As the operationalization of these multiple factors is difficult,
namely in terms of behavior, "results" are measured via what the
evidence reports as predictors for care/practices for glycemic control –
biochemical criteria provided by A1C testing (glycated hemoglobin testing). Therefore, A1C is
used as a diagnostic and monitoring tool for glycemic control. These criteria
can be influenced by multiple variables such as insulin sensitivity, an individual's
physiological characteristics, and the efficiency of doctor-patient
communication. Despite the limitations as mentioned above, the ADA recommends
A1C as the best test to determine how well a patient's glycemia is under
control.
As for A1C levels, studies conducted by
the Diabetes Control and Complications
Trial (DCCT) and by the United
Kingdom Prospective Diabetes Study (UKPDS) have shown that the lower the
A1C, the better the prognosis (International Diabetes Federation, 2017).
Currently, the criterion of 'the lower the A1C levels, the better' is no longer
widely accepted since values for A1C vary according to the patient, their age,
and associated comorbidities. Therefore, the A1C recommended values by the ADA
for young people without comorbidity is under 7%, and under 8% for older
individuals suffering from complications. When these scores are exceeded, the
DM patient will be considered as not having the disease under control, and,
from a clinical point of view, probably, glycemic control is not occurring.
The current study sought out to explore
whether there were differences between T1DM and T2DM patients in terms of
depressive symptoms, as well as the relationship between these symptoms and
glycemic control, considering that depressive symptoms may influence the degree
to which individuals engage in medical recommended procedures/behaviors.
Moreover, the association of duration of the disease and depressive symptoms
was also addressed.
Method
Participants
This
cross-sectional study included 347 individuals with a DM diagnosis (T1DM and
T2DM) attending consultations at the Department of Endocrinology, Diabetes, and
Metabolism of the Coimbra Hospital and University Centre (CHUC) and at the APDP
– Diabetes Portugal (Portuguese Diabetes Patients Association). Inclusion
criteria were age over 18 years old and a DM diagnosis for at least one year
(the assisting doctor reported DM diagnosis). The current sample was a
convenience sample.
Instruments
Sociodemographic
questionnaire (SDQ). The SDQ included questions regarding age, sex, marital status, and years
of education. Clinical data regarding A1C (metabolic control level) was also
collected.
Beck Depression
Inventory (BDI; Beck et al., 1961; Portuguese version by Vaz-Serra & Pio-Abreu, 1973). The BDI is a
widely used self-report measure of depressive symptoms composed of 21 groups of
statements addressing affective, cognitive, motivational, delusional, physical,
and functional (e.g., sleep pattern, weight loss, libido) symptoms. Data from
the BDI validation study in the Portuguese population showed that scores
between 0 and 9 indicate the absence of depression, between 10 and 20 slight
depressive states, between 21 and 30 moderate levels of depression and over 30
severe depression (Vaz-Serra & Pio-Abreu, 1973). In the current study, the BDI Cronbach alpha
was of .89.
Procedures
Participants' recruitment was carried out
directly at the Department of Endocrinology, Diabetes, and Metabolism (CHUC)
and the APDP, by healthcare professionals (physicians and psychologists) at the
beginning of the consultation. Eighteen months was set for data collection.
After receiving information regarding the study aims, the voluntary nature of
their participation, as well as anonymity and confidentiality, participants
gave their written informed consent and completed a set of self-report
instruments (paper-pencil format). The Ethical Committee of the Coimbra
Hospital and University Centre approved the study.
Statistical analysis
Data were
analyzed using the IBM Software Statistical
Package for Social Sciences (SPSS v.25). Independent samples t-tests
were used for mean comparisons of continuous variables, and chi-square tests
were used to compare frequencies. Odds ratios (ORs) with corresponding
95% confidence intervals (CIs) for each level of each variable (in
comparison with each variable's reference group) were analyzed. Pearson
correlations were calculated as preliminary analysis for conducting multiple
linear regression. Cohen's d effect
sizes were computed. Pearson correlations were used to explore the association
between duration of DM diagnosis and depressive symptoms, as well as A1C levels
(A1C ≤ 7%). Assumptions for conducting statistical analyses were verified.
Results
Table 1 presents the sociodemographic and clinical
characteristics of participants. The two groups showed differences regarding
age, with T2DM individuals being significantly older (M = 57.83; SD = 11.40;
Cohen’s d = 1.55), with ages ranging
from 18 to 81 years old. Regarding A1C, there were also significant differences
between T1DM (t = 2.40; p = .017; Cohen’s d = 0.26). T1DM participants presented higher A1C scores (M = 8.58; SD = 1.47) when compared to T2DM (M = 8.19; SD = 1.52).
|
Sociodemographic and Clinical Characteristics of
the Participants |
|
||||||||
|
|
T1DM (n = 159) |
|
T2DM (n = 188) |
t (345) |
p |
|
|||
|
|
M |
SD |
|
M |
SD |
|
|||
|
Age |
38.80 |
13.10 |
|
57.83 |
11.40 |
-14.47 |
< .001 |
|
|
|
A1C |
8.58 |
1.47 |
|
8.19 |
1.53 |
2.40 |
.017 |
|
|
|
|
n |
% |
|
n |
% |
2 |
p |
|
|
|
Gender |
|
|
|
|
|
2.19 |
.139 |
|
|
|
Men |
83 |
52.2 |
|
113 |
60.1 |
|
|
|
|
|
Women |
76 |
47.8 |
|
75 |
39.9 |
|
|
|
|
|
Marital status |
|
|
|
|
|
61.00 |
< .001 |
|
|
|
Single |
57 |
35.8 |
|
16 |
8.6 |
|
|
|
|
|
Married |
85 |
53.4 |
|
139 |
74.4 |
|
|
|
|
|
Divorced |
16 |
10.0 |
|
20 |
10.7 |
|
|
|
|
|
Widow |
1 |
0.6 |
|
12 |
6.4 |
|
|
|
|
|
Years of education |
|
|
|
|
|
50.64 |
< .001 |
|
|
|
1
– 4 |
8 |
5.1 |
|
51 |
27.3 |
|
|
|
|
|
5
– 6 |
9 |
5.7 |
|
27 |
14.4 |
|
|
|
|
|
7
– 9 |
20 |
12.7 |
|
29 |
15.5 |
|
|
|
|
|
10
– 12 |
56 |
35.4 |
|
36 |
19.3 |
|
|
|
|
|
Higher
Education |
65 |
41.1 |
|
44 |
23.5 |
|
|
|
|
|
Note. A1C = Glycated hemoglobin test; T1DM = Type 1 diabetes mellitus; T2DM = Type 2 diabetes
mellitus. Significant results
are in bold. |
|
||||||||
No differences were found between T1DM and T2DM groups in the BDI total score
(t = -1.82; p = .070; Cohen’s d =
0.20). However, a more detailed analysis regarding the BDI items, showed
statistically significant differences between T1DM and T2DM regarding symptoms
of work difficulty score (t = -4.74; p < .001; Cohen’s d = 0.52), insomnia score (t = -2.21; p = .028; Cohen’s d =
0.24), fatigability score (t = -2.40;
p = .017; Cohen’s d = 0.26), weight loss score (t = -2.08; p = .039; Cohen’s d =
0.22), and loss of libido score (t =
-4.76; p < .001; Cohen’s d = 0.51). For these symptoms mean
scores were higher in T2DM (Table 2). No other
differences were found between T1DM and T2DM concerning the other BDI symptoms.
|
Table
2 T1DM and T2DM Comparisons
Regarding Depressive Symptoms (BDI, Beck Depression Inventory) |
|
|||||
|
Items |
|
M |
SD |
t |
p |
|
|
BDI-15 |
T1DM |
0.43 |
0.72 |
-4.74 |
< .001 |
|
|
T2DM |
0.89 |
1.00 |
|
|||
|
BDI-16 |
T1DM |
0.63 |
0.86 |
-2.21 |
.028 |
|
|
T2DM |
0.86 |
1.04 |
|
|||
|
BDI-17 |
T1DM |
0.65 |
0.62 |
-2.40 |
.017 |
|
|
T2DM |
0.81 |
0.62 |
|
|||
|
BDI-19 |
T1DM |
0.31 |
0.69 |
-2.08 |
.039 |
|
|
T2DM |
0.49 |
0.90 |
|
|||
|
BDI-21 |
T1DM |
0.50 |
0.84 |
-4.76 |
< .001 |
|
|
T2DM |
0.99 |
1.04 |
|
|||
|
Note. T1DM = Type 1
diabetes mellitus; T2DM = Type 2 diabetes mellitus. |
|
The association between depressive symptoms and glycemic control in T1DM
patients was statistically significant (χ2
= 5.86; p = .015). T1DM patients
showing no depressive symptoms show 5.4 times more glycemic control than those
participants presenting depressive symptoms (OR = 5.4; IC95% =
1.20-24.21). As for T2DM, depressive symptoms were also associated with
glycemic control (χ2 = 6.58; p = .010). T2DM participants showing
depressive symptoms exhibit 2.5 times more glycemic control than those with T2DM
showing no depressive symptoms (OR = 2.5; IC95% = 1.251-5.053).
Associations between sex, age, marital status, years of education and glycemic
control were also explored as preliminary analyses for conducting a multiple
linear regression. Given that no significant associations were found (p >
.05) the regression analysis was not performed.
Finally, when considering the association of duration of the disease and
depressive symptoms, no significant correlations were found for either T1DM (r = -0.07; p = .650; R2 = 0.49%), or T2DM (r = -0.02; p = .826; R2 = 0.04%). The same pattern was found
for the correlation between the duration of DM diagnosis and glycemic control
for T1DM (r = -0.17; p = .236; R2 = 2.89%),
or T2DM (r = 0.08; p = .440; R2 = 0.64%).
Discussion
DM is a clinical condition with specific characteristics,
even when compared with other chronic pathologies. Whereas T1DM implies that a
patient will have earlier contact with the disease and its therapeutic demands,
T2DM obliges individuals to undergo significant changes regarding both pharmacological
treatment and lifestyle. These subsequent changes in behavior, such as eating
habits and physical activity levels, may lead to emotional reactivity. Thus,
the emotional impact when faced with a DM diagnosis and its treatment plan must
be taken into account when attempting to achieve a more holistic approach.
Common emotional reactions are anger, resentment, and depression, independently
from the etiology and age group, leading to significant psychosocial changes (Santos Filho et al., 2008). Indeed, the relationship between depression
and chronic diseases (Birk et al., 2019),
and depression and specifically DM has been frequently acknowledged in the
literature (Cox & Gonder-Frederick,
1992;
Fráguas et
al., 2009;
Góis, 2013; Saraiva, 2014).
In the current study, when comparing the sociodemographic
characteristics of participants presenting T1DM and T2DM, differences were
found in terms of age, marital status, and years of education. These
differences were somehow expected, given that the incidence of T2DM is higher
for older age groups. Regarding the comparison of A1C, differences were also
found between the groups, with T2DM patients showing more favorable glycemic
control scores. This finding may be attributable to the fact that control of
T2DM is easier to establish as the pancreas is still able to produce insulin;
this not being the case in T1DM.
Regarding the association between glycemic
control and depressive symptoms in T1DM and T2DM, a significant relationship
was found in both groups, which is in accordance to what has been reported in
the literature (Egbuonu et al., 2019;
Park et al.,
2004;
Picozzi & DeLuca, 2019; Santos et al., 2013). Nevertheless, in other studies,
depressive symptoms and glycemic control did not show a clinically significant
association (Braz et al., 2012;
Fisher et al., 2007). Similarly, emotional factors such as depression were not
associated in a significant way with DM glycemic control (Ramos
& Ferreira, 2011; Silva et al., 2005). Although studies addressing the
relationship between depressive symptoms and glycemic control in DM patients
have produced mixed results, in the current study, differences were found
between T1DM and T2DM patients. While these clinical conditions are manifestly
different, the glycemic control criteria used were the same.
Moreover, current study results were similar
to the ones found in other studies for T1DM (Tovar et
al., 2015);
for T2DM, they were in the opposite direction (Mansori et al., 2019). In T2DM patients, the
occurrence of depressive symptoms was associated with greater glycemic control.
Nevertheless, some aspects have to be considered in these findings'
interpretation. First, in the current sample, depressive symptoms results
showed subclinical significance as opposed to the ones identified in previous
studies (Braz et al., 2012).
More recently, Shrestha et al. (2020) conducted a systematic review and found
inconsistent results regarding the association between subthreshold depression
and self-care behaviors in T2DM. Also, it is relevant to note the fact that the
significant differences between the groups are fundamentally somatic.
Considering the symptoms, "work difficulty," "insomnia," "fatigability,"
"weight loss," and "loss of libido" it is hypothesized that
these might well correspond to the physical consequences of DM as opposed to
depressive symptoms. Some authors consider that the relationship between
depression and DM may be related to other biological changes, namely high
cortisol levels and changes in norepinephrine and serotonin levels (Talbot et
al., 1999;
Griffiths & Lustman, 1997).
Consequently, the relationship between
depressive symptoms and glycemic control found in T2DM patients may not express
this relationship. It may result from the need to adapt to lifestyle changes
and the physical consequences of DM. These lifestyle changes aiming for the
improvement of metabolic control may have consequences, and these can be
confounded with the previously mentioned BDI symptoms. Thom et al. (2019), in their literature review, suggest that
major depression may be seen as a systemic illness given that its
pathophysiology overlaps with other systemic medical conditions.
Furthermore, these results may also be
interpreted from an evolutionary perspective. Mood plays a mediating role
regarding the mobilization of survival strategies, and negative mood states may
lead to the activation of psycho-emotional resources when facing demanding
tasks (Rottenberg, 2014).
Therefore, it is hypothesized that T2DM patients showing higher levels of
depressive symptoms may be prone to pursue therapy and consequently improve
their glycemic control. The relationship between DM and depression can be
explained by disease management factors (Mezuk
et al., 2013), and the identification and treatment of depression in
DM patients are also highly recommended (Khan et al., 2019; Owens-Gary et al.,
2019).
The BDI is considered as an adequate
instrument for assessing depression in T1DM and T2DM patients (Lustman et al., 1997). However, it
is a general instrument and may not address specificities inherent to DM.
Furthermore, the BDI is a self-report measure, and this can be a limitation
given that more detailed information can be obtained via a structured
interview. In this context, the development of an assessment instrument able to
capture the emotional impact of DM specific features would be relevant in the
future. Other limitations to be acknowledged are the study's cross-sectional
design that does not allow causal conclusions to be drawn and the sample size.
Additionally, the study examines different
size groups of DM patients who have sought support at the APDP, and it can be
theorized that the contact with a patients' association may contribute to being
better informed and more integrated and, consequently, presenting lower levels
of depressive symptomatology. There are therapeutic factors that operate as
change promoters in group contexts, as would be the case of patients'
associations that support individuals with the disease (Yalom
& Leszcz, 2005). Nevertheless, additional research is needed
to clarify the role of being in touch with a patients' association in
depressive symptoms and glycemic control.
Conclusion
To sum, it is important to highlight the
distinction between depressive symptoms and the physical consequences inherent
to T2DM treatment, given that they may be confounded.
Acknowledgments | Agradecimentos: The authors would like to
thank all participants and professionals who cooperated in data collection.
Conflict of interest | Conflito de interesse: The
Authors declare that there is no conflict of interest.
Funding sources | Fontes de
financiamento: None
| nenhuma.
Contributes: IMC:
Study design; Preparation of measures and writing of the protocol; Recruitment
of participants; Statistical analysis; Supervision of the writing of the
manuscript and approval of the final manuscript. FD: Bibliographic research; Literature revision;
Statistical analysis; Writing of the manuscript. VR: Final review and approval of the manuscript.
AG: Statistical analysis; Writing, final revision, and approval of the
manuscript.
Beck, A., Ward, C., Mendelson, M., Mock, J.,
& Erbaugh, J. (1961). An inventory for measuring
depression. Archives of General Psychiatry, 4(6), 561–571.
https://doi.org/10.1001/archpsyc.1961.01710120031004
Birk, J. L., Kronish, I.
M., Moise, N., Falzon, L., Yoon, S., & Davidson,
K. W. (2019). Depression and multimorbidity: Considering temporal
characteristics of the associations between depression and multiple chronic
diseases. Health Psychology, 38(9), 802–811. https://doi.org/10.1037/hea0000737
Braz, J. M., Silva, R.M., Góis, C. F. L., Braz, T.
M., Santos, V., & Silva, L. A. S. M. (2012). Sintomas depressivos e adesão
ao tratamento entre pessoas com diabetes mellitus
tipo 2 [Depressive
symptoms and adherence to treatment among people with type 2 diabetes
mellitus]. Revista da Rede de Enfermagem do Nordeste, 13, 1092–1099. http://www.periodicos.ufc.br/rene/article/view/4108
Chireh, B., Li, M., & D'Arcy, C. (2019).
Diabetes increases the risk of depression: A systematic review, meta-analysis
and estimates of population attributable fractions based on prospective
studies. Preventive Medicine Reports, 14, 100822.
https://doi.org/10.1016/j.pmedr.2019.100822
Costa, J. A., Balga, R. S. M., Alfenas, R. C.
G., & Cotta, R. M. M. (2011). Promoção da saúde e
diabetes: discutindo a adesão e a motivação de indivíduos diabéticos
participantes de programas de saúde [Health promotion and
diabetes: Discussing the
adherence and motivation of
diabetics that participate in health programs]. Ciência & Saúde Coletiva, 16(3), 2001–2009. https://doi.org/10.1590/S1413-81232011000300034
Cox, D. J., & Gonder-Frederick, L.
(1992). Major
developments in behavioral diabetes research. Journal of Consulting Psychology,
60(4), 628–638. https://doi.org/10.1037//0022-006x.60.4.628
Egbuonu, I., Trief, P. M.,
Roe, C., & Weinstock, R. S. (2019). Glycemic outcomes related to depression
in adults with type 1 diabetes. Journal of Health Psychology. Advance
online publication. https://doi.org/10.1177/1359105319877298
Fráguas, R., Soares, S. M. S. R., & Bronstaein, M. D. (2009). Depressão e
diabetes mellitus [Depression and diabetes mellitus]. Revista de
Psiquiatria Clínica, 36(3), 93–99.
https://doi.org/10.1590/S0101-60832009000900005
Fisher, L., Skaff, M., Mullan, J., Arean, P., Mohr, D., Masharani, U., Glasgow, R., & Laurencin,
G. (2007). Clinical
depression versus distress among patients with type 2 diabetes: Not just a
question of semantics. Diabetes Care, 30(3), 542–548. https://doi.org/10.2337/dc06-1614
Góis, C. J. F. C. (2013). Estados depressivos em
diabetes tipo 2 [Doctoral dissertation,
Universidade de Lisboa]. Repositório da Universidade de Lisboa. https://repositorio.ul.pt/handle/10451/8976
Gonzalez, J. S., Safren, S. A., Cagliero, E.,
Wexler, D. J., Delahanty, L., Wittenberg, E., Blais, M. A., Meigs, J.
B., & Grant, R. W. (2007). Depression, self-care, and medication
adherence in type 2 diabetes: Relationships across the full range of symptom
severity. Diabetes Care, 30(9), 2222–2227. https://doi.org/10.2337/dc07-0158
Griffiths, L. S.,
& Lustman, P. J. (1997). Depression in women with
diabetes. Diabetes Spectrum, 10, 216–223.
http://journal.diabetes.org/diabetesspectrum/97v10n3/pg216.htm
Guedes, M. F. S.,
Sales-Peres, S. H. C., Negrato, C. A., Lauris, J. R. P., & Sá, L. M. (2016). Estilo de vida em pacientes portadores
de diabetes mellitus tipo 1: uma revisão sistemática
[Lifestyle of patients with diabetes mellitus type 1: A systematic review]. Ciência & Saúde Coletiva, 21(4), 1197–1206.
https://doi.org/10.1590/1413-81232015214.20242015
International
Diabetes Federation. (2020). IDF diabetes atlas (9th ed.) [e-book].
www.diabetesatlas.org
Kahanovitz,
L., Sluss, P. M., & Russell, S. J. (2017). Type 1
Diabetes — A clinical perspective. Point of Care, 16(1),
37–40. https://doi.org/10.1097/POC.0000000000000125
Khan, Z. D., Lutale, J., & Moledina, S. M.
(2019). Prevalence of depression and associated factors among diabetic patients
in an outpatient diabetes clinic. Psychiatry Journal, Article 2083196.
https://doi.org/10.1155/2019/2083196
Lustman, P. J., Clouse, R. E., Griffith, L. S.,
Carney, R. M., & Freedland, K. E. (1997). Screening for depression in
diabetes using the Beck Depression Inventory. Psychosomatic Medicine, 59(1),
24–31. https://doi.org/10.1097/00006842-199701000-00004
Mansori, K., Shiravand, N.,
Shadmani, F. K., Moradi, Y., Allahmoradi,
M., Ranjbaran, M., Ahmadi, S., Farahani, A., Samii, K., & Valipour, M.
(2019). Association between depression with glycemic control and its
complications in type 2 diabetes. Diabetes & Metabolic Syndrome:
Clinical Research & Reviews, 13(2), 1555–1560.
https://doi.org/10.1016/j.dsx.2019.02.010
Masek, B. J., & Janke, W. R. (1982).
Therapeutic adherence. In D. C. Russo & J. W. Varni
(Eds.), Behavioral pediatrics: Research and practice (pp. 375–395).
Plenum Press.
Mezuk, B., Johnson-Lawrence, V., Lee, H., Rafferty,
J. A., Abdou, C. M., Uzogara, E. E., & Jackson,
J. S. (2013). Ignorance is a bliss? Depression, antidepressants, and diagnosis
of prediabetes and type 2 diabetes. Health Psychology, 32(3), 254–263.
https://doi.org/10.1037/a0029014
Moreira, R. O., Papelbau, M., Appolinario, J. C.,
Matos, A. G., Coutinho, W. F., Meirelles, M., Ellinger, V. C. M., & Zagury,
L.
(2003). Diabetes Mellitus
e depressão: uma revisão sistemática [Diabetes mellitus and depression:
A systematic review]. Arquivo Brasileiro
de Endocrinologia e Metabolismo, 47(1), 19–29. https://doi.org/10.1590/S0004-27302003000100005
Nouwen, A., Adriaanse, M.
C., van Dam, K., Iversen,
M. M., Viechtbauer, W., Peyrot,
M., Caramlau, I., Kokoszka,
A., Kanc, K., de Groot, M.,
Nefs, G., Pouwer, F., &
the European Depression
in Diabetes (EDID) Research Consortium. (2019). Longitudinal associations between depression
and diabetes complications: A systematic review and meta‐analysis. Diabetic
Medicine, 36(12), 1562–1572. https://doi.org/10.1111/dme.14054
Owens-Gary, M. D.,
Zhang, X., Jawanda, S., Bullard, K. M., Allweiss, P., & Smith, B. D. (2019). The importance of
addressing depression and diabetes distress in adults with type 2 diabetes. Journal
of General Internal Medicine, 34(2), 320–324.
https://doi.org/10.1007/s11606-018-4705-2
Park, H., Hong, Y.,
Lee, H., & Sung, Y. (2004). Individuals with type 2 diabetes and depressive
symptoms exhibited lower adherence with self-care. Journal of Clinical
Epidemiology, 57(9), 978–984. https://doi.org/10.1016/j.jclinepi.2004.01.015
Picozzi, A., & DeLuca, F. (2019). Depression and
glycemic control in adolescent diabetics: Evaluating possible association
between depression and hemoglobin A1c. Public Health, 170, 32–37.
https://doi.org/10.1016/j.puhe.2019.02.005
Ramos, L., &
Ferreira, E. A. P. (2011). Emotional factors, life quality and adhesion of
treatment in adult with type 2 diabetes. Journal of Human Growth and
Development, 21(3), 867–877. http://pepsic.bvsalud. scielo.php?script=sci_arttext&pid=S0104-12822011000300013&lng=pt&nrm=iso&tlng=en
Rottenberg,
J. (2014). The depths: The evolutionary origins of the depression epidemic.
Basic Books.
Santos Filho, C. V.,
Rodrigues, W. H. C., & Santos, R. B. (2008). Papéis de autocuidado:
subsídios para enfermagem diante das reações emocionais dos portadores [Self-care roles – Subsidy to the nursing before
the emotional reactions of the diabetes
Mellitus carriers]. Escola Anna Nery Revista de Enfermagem, 12(1), 125–129. https://doi.org/10.1590/S1414-81452008000100019
Santos, F. R. M., Bernardo, V., Gabbay,
M. A. L., Dib, S. A., & Sigulem, D. (2013). The impact of knowledge about diabetes,
resilience and depression on glycemic control: A cross-sectional study among
adolescents and young adults with type 1 diabetes. Diabetology & Metabolic Syndrome, 5(55), 1–5. https://doi.org/10.1186/1758-5996-5-55
Saraiva, C. B. (2014). Um guia clínico nos
cuidados de saúde primários [A clinical guide for primary healthcare]. Lidel.
Shrestha, M., Ng,
A., Al-Ghareeb, A., Alenazi,
F., & Gray, R. (2020). Association between subthreshold depression and
self-care behaviors in people with type 2 diabetes: A systematic review of
observational studies. Systematic Reviews, 9(45), 1–9.
https://doi.org/10.1186/s13643-020-01302-z
Silva, I. (2006). Psicologia da diabetes [Diabetes
psychology]. Quarteto Editora.
Silva, I. (2010). Psicologia da diabetes [Diabetes
psychology]. Placebo, Editora Lda.
Silva, I., Cardoso, H., & Pais-Ribeiro, L.
(2005). Variáveis psicológicas associadas à adesão ao tratamento da diabetes mellitus [Psychological variables associated
to treatment adherence in
diabetes mellitus]. Psicologia, 18(2), 159–171.
https://doi.org/10.17575/rpsicol.v18i2.434
Son, J., Nyklíček, I., Pop, V. J. M., & Pouwer,
F. (2011). Testing the effectiveness of a mindfulness-based intervention to
reduce emotional distress in outpatients with diabetes (DiaMind):
Design of a randomized controlled trial. BMC Public Health, 11(131),
2–11. https://doi.org/10.1186/1471-2458-11-131
Talbot, F., Nouwen,
A., Gingras, J., Bélanger, A., & Audet, J. (1999). Relations of diabetes intrusiveness and
personal control to symptoms of depression among adults with diabetes. Health
Psychology, 18(5), 537–542.
https://doi.org/10.1037/0278-6133.18.5.537
Thom, R., Silbersweig, D. A., & Boland, R. J. (2019). Major
depressive disorder in medical illness: A review of assessment, prevalence, and
treatment options. Psychosomatic Medicine, 81(3), 246–255.
https://doi.org/10.1097/PSY.0000000000000678
Tovar, E., Rayens, M. K., Gokun, Y., &
Clark, M. (2015). Mediators of adherence among adults with comorbid diabetes
and depression: The role of self-efficacy and social support. Journal of
Health Psychology, 20(11), 1405–1415. https://doi.org/10.1177/1359105313512514
Vaz-Serra, A., & Pio-Abreu, J. L. (1973). Aferição dos quadros
clínicos depressivos. I – Ensaio de aplicação do "inventário depressivo de
Beck" a uma amostra portuguesa de doentes
deprimidos [Assessment of depressive clinical conditions.
I – Study of the "Beck's Depressive Inventory" in a Portuguese sample
of depressed patients]. Coimbra Médica, XX, 623–644.
Word Health
Organization. (2011). Use of glycated haemoglobin
[e-book].
http://www.who.int/cardiovascular_diseases/report-hba1c_2011_edited.pdf
Word Health
Organization. (2016). Global report on diabetes.
https://www.who.int/diabetes/global-report/en/
Word Health
Organization. (2003). Innovative care for chronic conditions: Action
structural components – world report.
https://www.who.int/chp/knowledge/publications/icccreport/en/
Yalom, I. D., & Leszcz, M. (2005). The
theory and practice of group psychotherapy. Basic Books.
Publicação em
Acesso Aberto © 2020. O(s) Autor(es). Este é um artigo de acesso aberto distribuído
sob a Licença Creative Commons Attribution, que
permite uso, distribuição e reprodução sem restrições em qualquer meio, desde
que o trabalho original seja devidamente citado. |
Open Access Publication © 2020. The Author(s).
This is an open access article distributed under the Creative Commons
Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium,
provided
the
original work is properly cited. |